



## 2022 Spring Advances in Neurology

### 5/13/2022

This activity was created to address the professional practice gaps listed below:

- Employing the latest evidence-based practices for secondary stroke prevention.
- Identifying the 8 or so new medications recently approved for the acute and preventive treatment of migraine.
- Recognizing the evidence for new therapeutic options for the treatment of memory disorders, including Alzheimer's disease.
- Utilizing the latest options for treatment of the motor symptoms of Parkinson disease.

#### 1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Disagree		Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [50-3.72]	(0)	(1) 2.00%	(12) 24.00%	(37) 74.00%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [50-3.70]	(0)	(1) 2.00%	(13) 26.00%	(36) 72.00%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [50-3.66]	(0)	(1) 2.00%	(15) 30.00%	(34) 68.00%

#### 2. Please elaborate on your previous answers. (31)

Newer advances in stroke such as statin withdrawal were mind blowing topics

Work with IDD population — neuro underlying syndromes and diseases processes very common- this symposium very relevant to practice

Presented newer and up to date information relevant to advancing practice

The presenters were excellent and provided thorough explanations of the latest practices and medications used to treat neurological conditions

will improve practice

The CME was very helpful for gaining new insights and knowledge regarding new advances in clinical Neurology

Definitely a wonderful learning experience!

Considering the use of TNK for acute stroke management

I have been understanding of the of which medications for most effective for hypertensive patients for stroke prevention.

venous thrombosis work up and detection

I'm a CMA and some of the things covered is out of my scope.

as an RN this information is helpful when caring for these types of patients

The topics were quite elaborative and insightful which provided a crystal clear understanding the well prevalent topics

The advances in neurology explained by the panel was simplified and easy to understand and replicate the same.

The seminar was really helpful and provided a new insight on the drug therapies.

Pay more attention to the secondary causes of stroke prevention to teach patients. I am very encouraged by the advances in treatments for myasthenia, stroke, tardive dyskinesia, and headache.

The knowledge I gained was wonderful.

As I am entering neurology residency, it was very interesting to learn about the topics that were discussed. Excellent presentations, to the point delivery. Thank you!

Very informative and well presented. The pediatric stroke lecture and the first lecture on Saturday especially (dementia, Parkinson, Alzheimer).

appreciate the updated information and discussion

A lot of great information from the team leading the way in stroke treatment.

Gained most knowledge regarding stroke as this is my primary patient population

The educational perspective totally changed and i was able to learn many new things. understanding genetic testing can be used

Learned new concepts, very valuable for teaching

**3. Please evaluate the effectiveness of the following speakers in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)**

	Poor	Fair	Good	Excellent
Arpita Lakhotia, MD [48-3.90]	(0)	(0)	(5) 10.42%	(43) 89.58%
Saurav Das, MD [48-3.88]	(0)	(0)	(6) 12.50%	(42) 87.50%
Kim Meyer, PhD [49-3.86]	(0)	(0)	(7) 14.29%	(42) 85.71%
Elizabeth Wise, APRN [47-3.85]	(0)	(0)	(7) 14.89%	(40) 85.11%
Larry Goldstein, MD [49-3.86]	(0)	(0)	(7) 14.29%	(42) 85.71%
Saad Hasan, MD [50-3.78]	(0)	(0)	(11) 22.00%	(39) 78.00%
Michael Haboubi, DO [50-3.78]	(0)	(1) 2.00%	(9) 18.00%	(40) 80.00%
Michael Sowell, MD [47-3.83]	(0)	(0)	(8) 17.02%	(39) 82.98%
Lahoma Prather, DNP, RN [47-3.89]	(0)	(0)	(5) 10.64%	(42) 89.36%
Peter Hedera, MD [46-3.87]	(0)	(0)	(6) 13.04%	(40) 86.96%

Tuan Vu, MD [47-3.83]	(0)	(0)	(8) 17.02%	(39) 82.98%
Dylan Brock, MD [46-3.87]	(0)	(0)	(6) 13.04%	(40) 86.96%

#### 4. Please elaborate on your previous answers. (26)

They were excellent

All were excellent

The presenters were all impressive and knowledgeable.

great presentations

All the speakers were very effective.

Amazing overall!

All speakers were great

The lecture's giving by the presenters provided the latest update data on their topics which was excellent.

knowledgeable and engaging speakers

I think all the speakers were excellent. The amount of material covered was perfect.

all provided valuable information in a good format for web based learning

Dr Arpita explained things in a streamlined way which was awesome.

All the speakers were commendable.

especially notable were Larry Goldstein, Peter Hedera, and Dylan Brock.

n/a

All very interesting, especially pediatric stroke because that is not an area I see in my practice.

All were very good presenters

All spoke amazingly

Dr. Goldstein review of the evaluation of risk factors of stroke were helpful.

as above

#### 5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (30)

None, I don't see stroke patients.

Sharing hand outs :)

Ongoing training with staff

More considerations when transferring stroke patients, also when giving tpa stroke prevention innovations

That will be done on a case by case basis.

i will try the newer meds for myasthenia

The PNES discussion really opened my eyes to the potentially wide prevalence of this condition and I strive to be more cognizant of the existence of this condition in people. educate fellow professionals on updates

Medications for the acute and chronic treatment of migraine.

Use of TNK, new migraine treatments, etc

When to refer patients for evaluation of possible PNES when indicated

Looking for venous thrombosis more frequently

Understanding thing for the patient view.

knowledge regarding BP control in stroke patients

I would like to work on a new protocol for FPC services to use to educate family members on Strokes

These new protocols and medications were explained according to various cases which helps us to think in a right way at the right time

New therapies

Will continue to keep up with treatments for myasthenia, dementia, and headaches.

new protocols

Movement disorder/TD treatment

Knowing sooner to consult with ped neuro for stroke like sx. Resource on who to refer to for

discussion of hemorrhages with patient and patient families will be more effective after more info from Kim Meyer

Potential indentification of pediatric stroke, venous stroke.

BP meds for stroke

Newer protocols and medicines.

use antihypertensive for effective for stroke provention

## **6. How certain are you that you will implement this change?**

**(37)**

N/A <sup>(5-</sup>  
13.51%)

Certain <sup>(17-</sup>  
45.95%)

Very Certain <sup>(12-</sup>  
32.43%)

Maybe <sup>(2-</sup>  
5.41%)

Not Certain <sup>(1-</sup>  
2.70%)

## **7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (20)**

N/A

De-myelinating disorder

Alzheimer's

Neuropsychological evaluation

pain management

Anything related to stroke

New updates on medications for Alzheimer's disease.  
Migraine, Parkinson's, MS  
continued stroke education  
New drug trials for Movement disorders  
Billing and coding for E & M and CPT codes in neurology.  
Stroke Guidelines  
seizure/epilepsy, PD  
cardiac issues, post COVID issues  
na  
Ms stroke  
parkinson disease  
More about management of stroke and its prevention.  
update on stroke prevention

**8. Were the patient recommendations based on acceptable practices in medicine?**

(38)

Yes <sup>(38-</sup>  
100.00%)

**9. If you answered No on the question above, please explain which recommendation(s) were not based on acceptable practices in medicine? (4)**

NA

N/A

**10. Do you think the presentation was without commercial bias?**

(38)

Yes <sup>(38-</sup>  
100.00%)

**11. If you answered No on the above question, please list the topics that were biased? (4)**

NA

N/A

**12. Please provide any additional comments you may have about this educational activity. (9)**

None

NA

This educational event should continue to review telemedicine update on patient evaluation and care for the management of seizures, dementia etc.

thank you for again offering this opportunity for continued education

This conference is always excellent and I look forward to it. I am glad to have the ability to zoom as I would not have been able to attend otherwise this year.

I really appreciate the speakers taking time to present these topics, and answering our questions after. I liked the quiz interaction during lecture but didn't have enough time (on phone) to give my answer. Great topics!

further discussion on the management of atrial fibrillation and the risk of stroke

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

Names or contact information of learners will not be shared with any ineligible company or its agents without the explicit consent of the individual learner.

We look forward to seeing you at future University of Louisville events. Thank you very much.

## 2022 Fall Advances in Neurology

### 10/8/2022

This activity was created to address the professional practice gaps listed below:

- Identifying the 8 or so new medications recently approved for the acute and preventive treatment of migraine.
- Demonstrating proficiency at the recognition, evaluation and management of neurotologic disorders.
- Recognizing and utilizing the latest options for treatment of the various types of brain tumors.
- Utilizing the latest options for treatment of the motor symptoms of movement disorders.
- Recognizing the latest options for evaluation and management of adults with Intellectual and Developmental Disabilities (IDD).
- Recognizing the evidence for new therapeutic options for the treatment of immune mediated disorders, including multiple sclerosis.
- Recognizing the evidence for diagnosis and new therapeutic options for the treatment of memory disorders.

#### 1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Disagree		Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [9-4.00]	(0)	(0)	(0)	(9)100%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [9-3.78]	(0)	(0)	(2) 22.22%	(7) 77.78%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [9-3.89]	(0)	(0)	(1) 11.11%	(8) 88.89%

#### 2. Please elaborate on your previous answers. (2)

Very informative presentations on all of the topics covered.

All of the speakers were very engaging, knowledgeable, and informative. Nice to have neurosurgery also as I learned more about brain tumor current treatments.

#### 3. Please evaluate the effectiveness of the following speakers in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

Poor      Fair      Good      Excellent

Brian Plato, DO [8-3.75]	(0)	(0)	(2) 25.00%	(6) 75.00%
Jerry Lin, MD [7-3.57]	(0)	(0)	(3) 42.86%	(4) 57.14%
Brian Williams, MD [7-3.86]	(0)	(0)	(1) 14.29%	(6) 85.71%
Jessica Solomon Sanders, MD [8-3.88]	(0)	(0)	(1) 12.50%	(7) 87.50%
Zain Guduru, MD [8-3.88]	(0)	(0)	(1) 12.50%	(7) 87.50%
Robert Friedland, MD [7-3.86]	(0)	(0)	(1) 14.29%	(6) 85.71%

#### 4. Please elaborate on your previous answers. (2)

Wonderful presentations by all of the speakers. The videos and imaging really help increase my understanding of the topics being discussed.

All very good.

#### 5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (5)

better rx

evaluate dizziness more thorough consider race in brain health more effectively

Learned about new medications that I'll be using in my practice.

It has helped me have a better understanding of current treatments of neurological disease and disorders. It is important to keep up with the latest information on brain tumors and to learn about autoimmune/paraneoplastic syndromes as a CRRN. The presentations on Intellectual & Developmental Disabilities and The IMPACT of Racism on Aging of the Brain were both interesting and very enlightening.

Think of autoimmune disorders especially when patients present with movement disorders and psychiatric symptoms.

#### 6. How certain are you that you will implement this change? (7)

(7)

Very Certain (4-  
57.14%)

Certain (2-  
28.57%)

N/A (1-  
14.29%)

#### 7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (5)

microbiota

Developmental delay and other disabilities and how it affects health, interesting topic

Fibromyalgia Multiple sclerosis

Anything related to advances in the care of neuro or spinal cord patients.

neuroimmunology is going to continue to dominate our field so more of this. Stroke and headache.



**8. Were the patient recommendations based on acceptable practices in medicine?**

(8)

Yes <sup>(8-</sup>  
100.00%)

**10. Do you think the presentation was without commercial bias?**

(8)

Yes <sup>(8-</sup>  
100.00%)

**12. Please provide any additional comments you may have about this educational activity. (1)**

Great presentation and topics

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

Names or contact information of learners will not be shared with any ineligible company or its agents without the explicit consent of the individual learner.

We look forward to seeing you at future University of Louisville events. Thank you very much.